Share this page

  • New centre of excellence for a global leader in consumer health
  • Brings together world leading academics in human behaviour and frontline healthcare professionals
  • Aims to help solve some of the most pressing challenges for health professionals

21st SEPTEMBER 2022: Haleon (LSE/NYSE: HLN) today launches the Haleon Centre for Human Sciences (“HCHS”), bringing together the expertise of practising health professionals and scientists, to address the behavioural challenges impacting everyday health.

Unveiled at the International Pharmaceutical Federation (FIP) congress in Seville, the Centre   will operate as a community of health professionals and specialists in behavioural science, health psychology and the social sciences. This collaboration will aim to solve some of the most pressing everyday health challenges.

The HCHS is the first major initiative for health professionals since Haleon’s launch as an independent, global leader in consumer health. Its mission is to support practicing health professionals - pharmacists, pharmacy assistants and dental professionals - in serving their patients and communities. Leveraging Haleon’s competitive advantage of combining trusted science with deep human understanding, the Centre will bring expertise in physiological science together with human sciences to deliver real world-solutions and tangible interventions, resulting in measurable improvements in health outcomes through sustained behavioural change.

The launch of the HCHS comes at a crucial time. A recent survey undertaken by Haleon revealed that 90% of pharmacists across Europe and the US believe that the role of the pharmacist has changed, requiring them to have greater expertise in influencing human behaviour and choices in patients’ health. 

How It Works

The HCHS community will design, pilot, implement and evaluate solutions in real world settings. It will tackle issues one at a time, starting with pain management for the inaugural programme. Pain is the most common reason people seek healthcare and is the leading cause of disability in the world [Lancet 2021].1 Haleon has long championed the role of pharmacists and pharmacy services in pain management and strongly believes that with the right support, an enhanced role would be of great benefit to patients and healthcare systems more broadly. Facilitated by Robert Horne, Professor of Behavioural Medicine at UCL School of Pharmacy, pharmacists can expect to see the first solution from the HCHS delivered in 2023.

Tess Player, VP Global Head of Expert/Health Professionals at Haleon, said:

As a global leader in consumer health, Haleon’s purpose is to deliver better everyday health with humanity. We know that some of the barriers to that are behavioural. The potential for the application of human sciences to help improve people’s health by influencing behavioural change, is astounding. The key to unlocking this lies with health professionals. While primarily students of medicine, their changing roles requires them to become experts in influencing patient behaviour. This is where we can help.

We have long heard from practising health professionals that they would benefit from greater opportunity and resources to upskill themselves in behavioural and social sciences in an easily accessible way. 91% of pharmacists would like more support to develop strategies for helping patients adopt new and sustainable health behaviours. With the launch of our Centre for Human Sciences, we are committing to removing this barrier so they can focus on improving everyday health outcomes in the communities they serve.” 

“Through a deep understanding of the human factors behind health decisions and behaviours, and the development of practical solutions, the Centre’s community can tackle some of the very real challenges pharmacy professionals experience.  This is just one example of how Haleon is delivering on its purpose and raising the bar in the level of support for health professionals, patients, and everyday health.”

Panel guest, Ivo Vlaev, Professor of Behavioural Science at Warwick Business School, said:

“The launch of the Haleon Centre for Human Sciences is an important and timely initiative as we know more than ever that the application of human sciences, including behavioural and social, can help improve people's health. This unique collaboration brings with it the opportunity to shift the self-care paradigm and drive better health outcomes.”

Health professionals are uniquely positioned to provide key insights to the health issue that need to be improved, intervention design and practical implementation, in order to drive enhanced care through empathy, compassion and sustained behaviour change.

As such, health professionals will have the opportunity to be involved in the Centre in several ways:

  • Sharing insights – through involvement in, and contribution to, the HCHS' multidisciplinary teams
  • Contributing to design thinking – through providing perspectives on key health challenges in their locality
  • Piloting interventions in the real world, within their healthcare practices
  • Becoming an advocate for the HCHS – through regional representation of the Centre's work

Practising health professionals can sign up to be involved in the Haleon Centre for Human Sciences by visiting here.2

About Haleon

Haleon (LSE: HLN) is a global leader in consumer health, with brands trusted by millions of consumers globally. The group employs over 22,000 people across 170 markets, who are united by Haleon’s purpose - to deliver better everyday health with humanity. Haleon’s product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

For more information, please visit  

Cautionary statement regarding forward-looking statements

Certain statements in this announcement relate to the future, including forward-looking statements relating to the Haleon Group’s financial position and strategy. Forward-looking statements give the Haleon Group’s current expectations or forecasts of future events. In some cases, these forward looking statements can be identified by the use of forward-looking terminology, including (without limitation) the terms “intend”, “aim”, “project”, “anticipate”, “estimate”, “plan”, “believe”, “expect”, “may”, “should”, “will”, “continue” or other similar words. These statements discuss future expectations concerning the Haleon Group’s results of operations or financial condition, or provide other forward-looking statements. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, dividend payments and financial results. Any forward-looking statements made by or on behalf of the Haleon Group speak only as of the date they are made.

These forward-looking statements are not guarantees or predictions of future performance, may be based on a number of assumptions (which may or may not themselves prove to be correct) and, by their nature, involve known and unknown risks, uncertainties and other factors, including the risk factors set out in the section entitled “Risk Factors” in the Haleon Prospectus and in “Item 3. Key Information — 3.D. Risk Factors” of Haleon’s registration statement on Form 20-F, many of which are beyond the Haleon Group’s control, and which may cause the actual results to differ materially from those expressed in the statements contained in this announcement. The Haleon Group’s actual results of operations, financial condition and the development of the business sectors in which the Haleon Group operates may differ materially from those expressed or implied in any forward-looking statement contained in this announcement due to certain factors including, but not limited to, domestic and global economic and business conditions, market-related risks pertaining to the consumer healthcare industry as a whole, the policies and actions of regulatory authorities, geopolitical developments, market developments, the impact of competition, technological development, inflation, deflation, foreign currency exchange rates, the timing, impact and other uncertainties of any future acquisitions, combinations or divestments within relevant industries, as well as the impact of tax and other legislation and other regulations in the jurisdictions in which the Haleon Group operates. In addition, even if the Haleon Group’s actual results of operations, financial condition and the development of the business sectors in which it operates are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of results or developments in subsequent periods.

Forward-looking statements contained in this announcement speak only as of the date of this announcement. Haleon expressly disclaims any obligation or undertaking to update these forward-looking statements contained in this announcement to reflect any change in their expectations or any change in events, conditions, or circumstances on which such statements are based unless required to do so by applicable law and regulations.

1 The Lancet , Series - Chronic pain. Available here:

2 Sign-up link for Practising health professionals who would like to be involved in the Haleon Centre for Human Sciences. here